Guido Oelkers appointed President and CEO at Sobi
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Guido Oelkers has been appointed President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough.
Guido Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH. He has extensive experience from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro, CEO of the specialty pharmaceutical company Invida and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group and Aventis (formerly Hoechst), where he began his career. Guido Oelkers was also a member of the Board of Directors for Meda. Guido Oelkers was born in 1965 and holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London. He complemented his postgraduate studies in Economics at London School of Economics and Political Science.
“We are delighted to announce Guido’s appointment. He has created substantial shareholder value in his various positions. Guido is a results-driven strategist and an entrepreneur at heart who has demonstrated impressive resourcefulness and creativity in his previous roles. Guido is the right person to further develop Sobi’s strategy as a pioneering biotechnology company, expanding upon the journey for our successful global brands, and realise the remarkable potential in our haemophilia franchise,” says Håkan Björklund, Chairman of Sobi. “The Board would also like to thank Geoffrey McDonough for his significant contribution and the remarkable value he has created during his term as CEO at Sobi.”
“Sobi is a unique company in the rare disease field. With a strong heritage, the company has been on an exciting journey over the years. I am delighted to be appointed CEO and look forward to work with the team at Sobi to continue on this path of strong commercial potential, innovation and development in order to serve rare disease patients and their families,” says Guido Oelkers.
Guido Oelkers is going to relocate to Stockholm, Sweden.
Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com .
|For more information please contact|
|Media relations||Investor relations|
|Morten Grøn, Vice President, Head of Communication||Jörgen Winroth, Vice President, Head of Investor Relations|
|+45 25 56 47 81||T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135|
This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Linda Holmström, Senior Communications Manager, at 08:00 am CET on 4 May 2017.
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com